MA55746A - Molécules multispécifiques ciblant cll-1 - Google Patents

Molécules multispécifiques ciblant cll-1

Info

Publication number
MA55746A
MA55746A MA055746A MA55746A MA55746A MA 55746 A MA55746 A MA 55746A MA 055746 A MA055746 A MA 055746A MA 55746 A MA55746 A MA 55746A MA 55746 A MA55746 A MA 55746A
Authority
MA
Morocco
Prior art keywords
multispecific molecules
molecules targeting
cll
targeting cll
multispecific
Prior art date
Application number
MA055746A
Other languages
English (en)
Inventor
Michael Daley
Hilmar Ebersbach
Julia Jascur
Qilong Wu
Qiumei Yang
Jiquan Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA55746A publication Critical patent/MA55746A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
MA055746A 2016-01-21 2017-01-20 Molécules multispécifiques ciblant cll-1 MA55746A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016071599 2016-01-21

Publications (1)

Publication Number Publication Date
MA55746A true MA55746A (fr) 2022-03-02

Family

ID=57915029

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055746A MA55746A (fr) 2016-01-21 2017-01-20 Molécules multispécifiques ciblant cll-1

Country Status (5)

Country Link
US (1) US20210198368A1 (fr)
EP (2) EP3851457A1 (fr)
ES (1) ES2847155T3 (fr)
MA (1) MA55746A (fr)
WO (1) WO2017125897A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
KR102661320B1 (ko) * 2017-06-05 2024-05-03 얀센 바이오테크 인코포레이티드 이중특이성 항체 생성을 위한 표면 전하 조작 방법
CN111432832A (zh) * 2017-09-14 2020-07-17 蜻蜓疗法股份有限公司 结合nkg2d、cd16和c-型凝集素样分子-1(cll-1)的蛋白质
CA3084518A1 (fr) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Anticorps a domaine unique et des variants de celui-ci diriges contre pd-1
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
CN112424441B (zh) * 2018-05-14 2023-05-09 昂科医药 抗cd24组合物及其用途
WO2020052542A1 (fr) * 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique contre cll1 et leurs constructions
CA3114707A1 (fr) * 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Molecules de recruteurs de cellules nk et leurs methodes d'utilisation
US20220169728A1 (en) * 2019-01-28 2022-06-02 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
US20220251176A1 (en) * 2019-03-29 2022-08-11 Green Cross Corporation Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
JP2022531306A (ja) * 2019-05-04 2022-07-06 インヒブルクス インコーポレイテッド ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
TW202208428A (zh) * 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991003493A1 (fr) 1989-08-29 1991-03-21 The University Of Southampton CONJUGUES F(ab)3 ou F(ab)4 bi ou trispécifiques
WO1991005548A1 (fr) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Composition a liberation entretenue pour proteines macromoleculaires
WO1991006570A1 (fr) 1989-10-25 1991-05-16 The University Of Melbourne MOLECULES RECEPTRICES Fc HYBRIDES
CA2071867A1 (fr) 1989-11-06 1991-05-07 Edith Mathiowitz Mode de fabrication de microspheres proteiniques
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
CA2074825C (fr) 1990-12-14 2005-04-12 Daniel J. Capon Chaines chimeriques pour cheminements de signaux de recepteurs
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0617706B1 (fr) 1991-11-25 2001-10-17 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
EP0746609A4 (fr) 1991-12-17 1997-12-17 Genpharm Int Animaux transgeniques non humains capables de produire des anticorps heterologues
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2128511C (fr) 1992-01-23 2006-11-07 Andreas Pluckthun Proteines de fusion comportant des fragments d'anticorps monomeriques et dimeriques
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2135408A1 (fr) 1992-05-08 1993-11-25 Peter C. Keck Analogues de proteines multivalentes chimeriques et modes d'utilisation
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994007921A1 (fr) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Polypeptide se fixant a une cible
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0754225A4 (fr) 1993-04-26 2001-01-31 Genpharm Int Animaux transgeniques capables de produire des anticorps heterologues
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
EP0770135A1 (fr) 1994-07-29 1997-05-02 Smithkline Beecham Plc Nouveaux composes
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996013583A2 (fr) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Hetero-association ciblee de proteines recombinees et de complexes fonctionnels
CA2207961A1 (fr) 1995-01-05 1996-07-11 Robert J. Levy Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0827544B1 (fr) 1995-05-23 2004-08-18 MorphoSys AG Proteines multimeres
CA2230494A1 (fr) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition se pretant a la liberation prolongee d'un agent
CN1173878A (zh) 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
WO1997038102A1 (fr) 1996-04-04 1997-10-16 Unilever Plc Proteine, polyvalente et a specificites multiples, de fixation sur un antigene
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
PT1012280E (pt) 1997-06-11 2005-02-28 Borean Pharma As Modulo de trimerizacao
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999023221A2 (fr) 1997-10-27 1999-05-14 Unilever Plc Proteines multivalentes de fixation de l'antigene
WO1999037791A1 (fr) 1998-01-23 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Derives d'anticorps a usages multiples
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO1999066903A2 (fr) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
DK1100830T3 (da) 1998-07-28 2004-01-19 Micromet Ag Heterominiantistoffer
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
CA2405709A1 (fr) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Proteines fusionnees a l'albumine
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2002002781A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteines de fusion heterodimeres
CN1461344A (zh) 2000-07-25 2003-12-10 免疫医疗公司 多价靶结合蛋白
US20040242847A1 (en) 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002247826A1 (en) 2001-03-13 2002-09-24 University College London Specific binding members
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
US20030211078A1 (en) 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs
EP1487879B1 (fr) 2002-03-01 2012-12-26 Immunomedics, Inc. Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
JP4386741B2 (ja) 2002-04-15 2009-12-16 中外製薬株式会社 ｓｃＤｂライブラリーの作成方法
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
EP1618181B1 (fr) 2003-04-22 2014-10-15 IBC Pharmaceuticals Complexe proteinique polyvalent
WO2005000898A2 (fr) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Purification et synthese preferentielle de molecules de liaison
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
EP2272566A3 (fr) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation d'anticorps
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
WO2005035586A1 (fr) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition proteique hybride
US20050136051A1 (en) 2003-12-22 2005-06-23 Bernard Scallon Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
US7111546B2 (en) 2004-03-19 2006-09-26 Lifetime Brands, Inc. Salad spinner with improved drive assembly
WO2006002438A2 (fr) 2004-06-03 2006-01-05 Medarex, Inc. Anticorps humains monoclonaux anti-recepteur gamma (cd64) de la region fc
EP1786918A4 (fr) 2004-07-17 2009-02-11 Imclone Systems Inc Nouveau anticorps bispecifique tetravalent
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
JP5011277B2 (ja) 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
WO2006113665A2 (fr) 2005-04-15 2006-10-26 Macrogenics, Inc. Di-anticorps covalents et leurs utilisations
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602005018477D1 (de) 2005-08-26 2010-02-04 Pls Design Gmbh Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
WO2007044887A2 (fr) 2005-10-11 2007-04-19 Transtarget, Inc. Procede de production d'une population homogene d'anticorps bispecifiques tetravalents
WO2007062466A1 (fr) 2005-11-29 2007-06-07 The University Of Sydney Demi-corps : agents thérapeutiques activés par dimérisation
AU2007215013A1 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Functional antibodies
JP5374359B2 (ja) 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
EP4218801A3 (fr) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
EP2799449A1 (fr) 2006-05-25 2014-11-05 Bayer Intellectual Property GmbH Complexes moléculaires dimères
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
CA3149553C (fr) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
EP2078040B1 (fr) 2006-11-02 2017-06-28 Daniel J. Capon Procédé de production de polypeptides hybrides présentant des parties mobiles
WO2008119353A1 (fr) 2007-03-29 2008-10-09 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
US20110189203A1 (en) 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs
ES2614284T3 (es) 2007-11-30 2017-05-30 Glaxo Group Limited Construcciones de unión a antígenos
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2235064B1 (fr) 2008-01-07 2015-11-25 Amgen Inc. Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
CA2722466A1 (fr) 2008-04-29 2009-11-05 Tariq Ghayur Immunoglobulines a double domaine variable et utilisations
BRPI0919840B1 (pt) 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR101930964B1 (ko) 2010-04-20 2018-12-19 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
EP3674320A3 (fr) 2011-10-27 2020-08-12 Genmab A/S Production de proteines heterodimeres
FR2987254B1 (fr) 2012-02-24 2015-06-12 Helgoual Ch Guy L Dispositif endoscopique destine notamment a un usage medical.
EP3786183A3 (fr) 2012-06-15 2021-06-09 Imaginab, Inc. Constructions de liaison à l'antigène pour cd3
CN105051066B (zh) 2012-09-27 2019-08-06 美勒斯公司 作为T细胞衔接器的双特异性IgG抗体
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CN110420333A (zh) * 2013-03-14 2019-11-08 斯克利普斯研究所 靶向剂抗体偶联物及其用途
EP3514178A1 (fr) 2013-03-15 2019-07-24 Novartis AG Conjugués anticorps-médicament
EP2840091A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
EP2839842A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
RU2741120C2 (ru) * 2014-07-21 2021-01-22 Новартис Аг Лечение рака с использованием химерного антигенного рецептора cll-1
CA2958479A1 (fr) * 2014-09-12 2016-03-17 Genentech, Inc. Anticorps anti-cll-1 et immunoconjugues
US10501545B2 (en) * 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use

Also Published As

Publication number Publication date
EP3405492A1 (fr) 2018-11-28
US20210198368A1 (en) 2021-07-01
EP3851457A1 (fr) 2021-07-21
WO2017125897A1 (fr) 2017-07-27
EP3405492B1 (fr) 2020-10-21
ES2847155T3 (es) 2021-08-02

Similar Documents

Publication Publication Date Title
MA55746A (fr) Molécules multispécifiques ciblant cll-1
DK3433368T3 (da) Transreplikerende rna
DK3268047T3 (da) Amatoxin/antistof-konjugater
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3234134T3 (da) Målrettet rna-redigering
DK3131928T3 (da) Trifunktionelt antigenbindende molekyle
DK3129067T3 (da) Sitespecifik glycomodificering af målsøgningsdele
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3331528T3 (da) Muskarinagonister
DK3262066T4 (da) Genterapi
DK3310450T3 (da) Olie-vand-separator
DK3242685T3 (da) Cxcr4-bindende molekyler
DK3105250T3 (da) Multispecifikke iga-bindingsmolekyler
DK3270930T3 (da) Præeklampsi
DK3407944T3 (da) Forstøver
FI20165867A (fi) Valoherkiste
DK3292136T3 (da) Penicillin-g-acylaser
DK3276177T3 (da) Spiralhuspumpe
DE112015006486A5 (de) Inkubationsrinne
FR3052670B3 (fr) Nebuliseur
DK3318308T3 (da) Badmintonketsjer
DE112016005599A5 (de) Strahlungsgrill
DK3331600T3 (da) Kateter
CR20180079A (es) Moléculas de fusión